Skip to main
LLY
LLY logo

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly demonstrated a robust financial performance in the second quarter of 2025, surpassing expectations on both revenue and earnings while also raising its full-year guidance. Notably, Mounjaro's international sales surged by 60% quarter-over-quarter, fueled by successful market entries in Brazil, Mexico, and India, suggesting a strong growth trajectory for this product. Additionally, the anticipated launch of orforglipron, an oral GLP-1 option, is expected to enhance the company's competitive edge in the cardiometabolic market, further bolstering its revenue potential.

Bears say

Eli Lilly faces significant downside risks that contribute to a negative outlook on its stock, including potential pricing pressures and a disappointing trajectory for its key product, tirzepatide (Mounjaro). The company has also reported reduced prescription volumes for Zepbound, which is anticipated to hinder volumetric growth in the upcoming quarter. Furthermore, increasing competition from products like orforglipron, which poses a substantial threat to established offerings such as Ozempic, exacerbates these concerns regarding future revenue generation.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,059.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,059.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.